Ceri is Head of the College of Human and Health Sciences and Professor of Health Economics at Swansea Centre for Health Economics (SCHE).
SCHE combines significant qualitative skills, expertise in real world data mining and analysis and health policy and undertakes research and consultancy services for organisations engaged in the development and delivery of health care interventions and services. SCHE has strong relationships with health care decision making across a wide therapeutic base - including clinical specialists, academics, healthcare management and within HTA agencies. These activities have been backed by an extensive portfolio of publications in the fields of health economics and health and social policy, along with bespoke reports for companies and agencies that, in many cases, have informed submissions to NICE and other assessment agencies for technology appraisal.
He is a non-executive member of Abertawe Bro Morgannwg Health Board and a member of the Bevan Commission, established by the Welsh Minister of Health and Social Services on the 60th anniversary of the.
He is also a member of the 1000 Lives+ Programme Board and the Management Board of the NICE Collaborating Centre for Cancer and has recently been a member of NICE Programme Development Groups on a range of public health issues.
Up until November 2011 he was the health economics member of the All Wales Medicines Strategy Group (AWMSG), which advises the Welsh Minster of Health and Social Services on matters relating to prescribing decisions and medicines management, and was the Vice Chair of its New Medicines Group, which appraises all eligible new, licensed medicines, available for use in the NHS, and which makes recommendations to AWMSG.
He is currently undertaking a review for Minister on the assessment of orphan and ultra-orphan drugs and their accessibility for patients in Wales.